FzioMed Inc announces new patent issuance in the European Union.

SAN LUIS OBISPO, California—July 21st, 2014—FzioMed, Inc., a manufacturer and marketer of synthetic biomaterials is pleased to announce the issuance of a new patent in Europe, ‘Chemically Activated Carboxypolysaccharides and Uses’.

This invention relates to derivatized carboxypolysaccharides (CPS) and their uses in gels and films incorporating polyethylene oxide (PEO) for drug delivery, and for hemostatic and anti-adhesion preparations. More specifically, this invention relates to compositions comprising composites of carboxymethylcellulose (CMC) and polyethylene oxide (PEO).

These covalently or ionically cross-linked compositions containing CMC-PEO are very versatile and can be used in medical devices such as injectable void filling materials for tissue expansion or repair, load-bearing materials, anti-adhesion compositions, hemostatic compositions, and drug delivery vehicles.  

“This new patent allows more options to expand the use of CMC and PEO,” said John Krelle, President and CEO of FzioMed. “Areas of particular interest are as delivery vehicles for controlled release of bioactive substances such as, growth factors, active peptides, genes, cells, antibiotics, hormones and steroids. Physio-chemical properties may also be fine-tuned including, bioadhesion, bioresorbability, viscosity and interpenetration.”

The History of CMC and PEO use

CMC and PEO combinations have been sold by FzioMed for over a decade in more than 70 countries. Oxiplex®, also known as MediShield and Oxiplex/SP®, has been used in over 350,000 discectomy surgeries to reduce pain, adhesions and neurological symptoms following this procedure. It has been shown to be safe and effective in several peer reviewed, published clinical trials. MediShield is distributed outside the U.S. (OUS) by Medtronic and Oxiplex/SP is distributed by DePuy, a division of Johnson and Johnson.  It remains under review by FDA for approval in the United States.

Intercoat® is indicated for the reduction of pain and adhesions following gynecological and general surgery and is marketed by Ethicon, a division of Johnson and Johnson.              

Dynavisc® is approved in several countries OUS to reduce adhesions following tendon and peripheral nerve surgery.

About FzioMed

FzioMed is a privately held medical device company founded in 1996.  The Company develops, manufactures and commercializes absorbable surgical biomaterials based on its patented polymer science.  FzioMed adhesion barriers are used in many surgical applications including spine, orthopedics, hand, tendon, peripheral nerve, gynecology and general surgery.  Its spine gel is the number one adhesion barrier gel for spine surgery worldwide and is distributed by Medtronic, DePuy (a division of Johnson & Johnson) and other independent distributors.  For more information please visit www.fziomed.com

FzioMed®, Oxiplex®, Oxiplex/SP® and Dynavisc® are registered trademarks of FzioMed, Inc. Intercoat® is a trademark of Johnson and Johnson. MediShield™ is a trademark of Medtronic Sofamor Danek USA, Inc.


Contact:  FzioMed, Inc. 805.546.0610
John Krelle, President & CEO